Pipeline of Key Proprietary Products

We have a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer.

Development Candidates

Preclinical Phase 1 Phase 2 Phase 3 Regulatory

Review

ALKS 3831

Schizophrenia / Bipolar I Disorder* ALKS 4230

Oncology (Intravenous Dosing) Selective HDAC Inhibitors

Neurodegenerative Disorders (Orphan) *PDUFA target action date Nov. 15, 2020 Schizophrenia / Bipolar I Disorder*Oncology (Intravenous Dosing)Neurodegenerative Disorders (Orphan)